SHANGHAI, China, November 3,2026—— Duality Biotherapeutics, Inc. (DualityBio, HKEX: 09606, “the company”), a global innovator in antibody-drug conjugates (ADCs), today announced a strategic collaboration with Tencent Cloud Computing (Beijing) Co., Ltd. The parties will combine DualityBio's proprietary AI model platforms, experimental data and drug R&D capabilities with Tencent's strengths in AI engineering, high-performance computing and agent platforms. The collaboration will span AI for Science, cloud and AI infrastructure, and enterprise data and knowledge systems, with the aim of embedding AI across the entire innovative drug R&D value chain, from drug discovery through global clinical development.

As one of the inaugural ecosystem partners of Tencent Health’s newly launched BioNexus, DualityBio will leverage its capabilities and experience in ADC and next-generation conjugated drug development, proprietary data, in-house AI models, and high-throughput wet-lab experimentation to contribute models, tools, and real-world R&D use cases to the BioNexus ecosystem. Together, the parties aim to advance the practical application of AI across innovative drug discovery and development.

Building a Next-Generation, AI-Powered ADC R&D Engine

DualityBio is one of the world's leading ADC innovators. It has established four proprietary technology platforms - DITAC, DIBAC, DIMAC and DUPAC - and a pipeline spanning oncology and autoimmune diseases. The Company has 10 clinical-stage assets, is conducting global multicenter clinical trials in approximately 20 countries, and has entered into collaborations with global partners including BioNTech, GSK, Genentech and BeiGene, with an aggregate potential transaction value exceeding US$7 billion.

ADCs comprise antibodies, linkers and payloads. Multiple interdependent parameters, including conjugation chemistry, stability and release kinetics, create an exponentially large design space, making ADCs particularly well suited to AI-enabled drug design. Drawing on its R&D experience from molecular design through global clinical development, DualityBio has built proprietary AI platforms including DualSight, DeepDetect and DBNexus(TM), and is working with Tsinghua Shenzhen International Graduate School to explore a purpose-built foundation model for pathology. The Company is also expanding its high-throughput wet-lab capabilities to accelerate the validation of AI-designed candidates and support the continuous iteration of its proprietary models. In parallel, DualityBio is advancing the application of AI in global multicenter clinical development to improve R&D efficiency and the quality of decision-making.

Creating a Closed-Loop R&D System: AI Design, Experimental Validation, Data Feedback and Model Iteration 

The parties will combine DualityBio's drug R&D expertise, proprietary data, in-house AI models and wet-lab validation capabilities with Tencent's life-science algorithms, foundation models, AI engineering capabilities and large-scale computing infrastructure to jointly develop industrial-grade AI models for innovative drug R&D. Together, they will establish a continuously learning closed loop encompassing AI design, high-throughput experimentation, data feedback and model iteration. Molecules designed by AI will be rapidly validated on DualityBio's platforms, with experimental results fed back into the models to drive continuous improvement. 

Focusing on critical stages of drug R&D, the parties will explore the use of AI in areas including the design and optimization of novel molecules, the development of multispecific conjugated therapeutics, antibody engineering and developability prediction, thereby expanding the innovation frontier for next-generation conjugated therapeutics.

Strengthening AI-Native R&D and Operational Infrastructure 

The parties will collaborate on cloud infrastructure, AI computing, model and agent platforms, and enterprise data and knowledge systems. Tencent Cloud will leverage capabilities including its TI-ONE platform, TACO acceleration framework and agent technologies to support the training and deployment of DualityBio's AI R&D models. 

The parties will also use agent platforms to build enterprise-grade intelligent assistants and automated workflows. Through data governance and knowledge-base development, they will connect data and knowledge with R&D and operational use cases, laying the foundation for AI-native ways of working across the organization.

Dr. Yang Qiu, Chief Scientific Officer and General Manager of DualityBio US, said: “AI is reshaping innovative drug R&D. Its transformative potential must be realized in real-world, complex, industrial-scale R&D settings and ultimately translated into new medicines with meaningful clinical value. DualityBio continues to strengthen its in-house AI capabilities by deeply integrating proprietary models, advanced drug design, proprietary data and high-throughput experimental validation to build an AI-native R&D system that continuously learns and evolves. Through this collaboration with Tencent, we will further combine our respective strengths in scientific innovation, AI R&D, engineering and computing to accelerate the translation of AI technologies into drug innovation and develop the next generation of breakthrough therapies for patients worldwide.”

Wu Wenda, President of Tencent Health and Head of Tencent Life Sciences Lab, said: “Artificial intelligence is rapidly moving into the core of scientific research and industrial innovation. Its full value can only be realized through deep integration with high-quality data, domain expertise and real-world use cases. DualityBio has built deep innovation capabilities, proprietary experimental datasets and validation systems in ADCs and novel conjugated therapeutics. Tencent looks forward to combining its expertise in large language models, computing and cloud infrastructure with DualityBio's drug R&D capabilities to explore practical pathways for applying AI to innovative drug development.”

About DualityBio

DualityBio is a clinical-stage innovative biopharmaceutical company focused on developing next-generation ADCs for patients with cancer and autoimmune diseases. The Company has successfully established multiple next-generation ADC technology platforms with global intellectual property rights. Based on deep research into disease biology, DualityBio has built a broad clinical-stage ADC pipeline and is conducting global multicenter clinical trials across approximately 20 countries, with more than 3,500 patients enrolled. The Company has also entered into multiple global licensing collaborations with leading pharmaceutical companies and innovative biopharmaceutical companies. As a global ADC innovation engine, DualityBio continues to develop next-generation ADCs, including bispecific ADCs, novel-mechanism payload ADCs and autoimmune disease ADCs.

For more information, please visit: www.dualitybiologics.com

Media Contact: PR@dualitybiologics.com

Investor Contact: IR@dualitybiologics.com